These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38793681)

  • 1. Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020-2021.
    Dawe J; Gorton C; Lewis R; Richmond JA; Wilkinson AL; Pedrana A; Stoové M; Doyle JS; Russell D
    Viruses; 2024 May; 16(5):. PubMed ID: 38793681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022.
    Dawe J; Hughes M; Christensen S; Walsh L; Richmond JA; Pedrana A; Wilkinson AL; Owen L; Doyle JS;
    BMC Public Health; 2023 Nov; 23(1):2289. PubMed ID: 37985979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial incentives to increase engagement across the hepatitis C care cascade among people at risk of or diagnosed with hepatitis C: A systematic review.
    Shen C; Dawe J; Traeger MW; Sacks-Davis R; Pedrana AE; Doyle JS; Hellard ME; Stoové M
    Int J Drug Policy; 2024 Nov; 133():104562. PubMed ID: 39299141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study.
    Fathima P; Jones M; D'Souza R; Totterdell J; Andric N; Abbott P; Norman R; Howard K; Cheng W; Pedrana A; Doyle JS; Davies J; Snelling T
    Trials; 2024 Jun; 25(1):387. PubMed ID: 38886819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
    Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
    MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
    Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
    Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
    Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
    Wade AJ; Macdonald DM; Doyle JS; Gordon A; Roberts SK; Thompson AJ; Hellard ME
    PLoS One; 2015; 10(11):e0142770. PubMed ID: 26562516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    Palmer AY; Chan K; Gold J; Layton C; Elsum I; Hellard M; Stoove M; Doyle JS; Pedrana A; Scott N;
    J Viral Hepat; 2021 Nov; 28(11):1624-1634. PubMed ID: 34415639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
    Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
    Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
    Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A
    Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial.
    Day CA; Shanahan M; Wand H; Topp L; Haber PS; Rodgers C; Deacon R; Walsh N; Kaldor J; van Beek I; Maher L;
    J Clin Virol; 2016 Jan; 74():66-72. PubMed ID: 26679830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia.
    Topp L; Day CA; Wand H; Deacon RM; van Beek I; Haber PS; Shanahan M; Rodgers C; Maher L;
    Prev Med; 2013 Oct; 57(4):297-303. PubMed ID: 23639625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
    Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
    J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
    O'Keefe D; Gunn J; Ryan K; Djordjevic F; Kerr P; Gold J; Elsum I; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana AE
    BMJ Open; 2022 Jan; 12(1):e057618. PubMed ID: 34983773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.